CHIP-BCIS3 coverage argues elective Impella CP unloading in high-risk PCI did not reduce major adverse events and may increase harm, including higher cardiovascular death, prompting debate about strategy and patient selection.
The Impella CP percutaneous left ventricular assist device doesn't reduce major adverse events when used in the setting of high-risk PCI.
In fact, it can cause more harm, with the risk of CV death significantly higher in the Impella group, based on the CHIP-BCIS3 trial.
Immediate complete revasc ⬆️periproc MI;CHIP is judgment & not MCS: my mentor used to say “In CHIP: less is more”
“doesn't reduce major adverse events”
“it can cause more harm”
“risk of CV death significantly higher in the Impella group”
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare